<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742166</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_8891_IPAD Study</org_study_id>
    <nct_id>NCT04742166</nct_id>
  </id_info>
  <brief_title>Impact of Side to Side Gastrojejunostomy on the Rate of Delayed Gastric Emptying After Pancreaticoduodenectomy (IPAD)</brief_title>
  <acronym>IPAD</acronym>
  <official_title>Impact of Side to Side Gastrojejunostomy on the Rate of Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective bi-centric randomized open-label study comparing side to side and end to side&#xD;
      gastrojejunostomy in pancreaticoduodenectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed gastric emptying is one of the main complications occurring after&#xD;
      pancreatodudodenectomy, the incidence of which is estimated between 10 and 40% in the&#xD;
      literature. Its occurrence leads to an alteration in post-operative quality of life&#xD;
      (maintenance or resting of the nasogastric tube) and is the primary reason an increase in the&#xD;
      length of hospital stay and therefore the cost of treatment. In addition, it predisposes to&#xD;
      the risk of inhalation pneumopathy, which increases the risk of post-operative death. Various&#xD;
      technical surgical points have been suggested by retrospective studies to reduce its&#xD;
      incidence (pyloric preservation, respect for the left gastric vein, ante-colic positioning of&#xD;
      the Child's handle, making a Y-shaped handle) but without ever being validated in randomized&#xD;
      prospective studies.&#xD;
&#xD;
      Recently three retrospective studies have highlighted the interest of performing a side to&#xD;
      side l rather than an end to side gastro-jejunal anastomosis to reduce the rate of&#xD;
      post-operative delayed gastric emptying.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative delayed gastric emptying</measure>
    <time_frame>Day 90</time_frame>
    <description>Occurrence of post-operative delayed gastric emptying (classified to the International Study Group for Pancreatic Surgery (ISGPS))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clavien-Dindo complications</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic fistula</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Occurence of pancreatic fistula (classified according to the ISGPS classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary fistula</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Occurrence of biliary fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemorrhage</measure>
    <time_frame>Up to day 90</time_frame>
    <description>Occurrence of haemorrhage according to the ISGPS classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake (liquid and solid)</measure>
    <time_frame>Up to five days after surgery</time_frame>
    <description>Time to oral food intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First gas</measure>
    <time_frame>Up to five days after surgery</time_frame>
    <description>Time to the emission of the first gas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-operative to 3-month post-operative weight ratio</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin and prealbumin levels</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Quality of Life Score for Digestive Pathologies</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Quality of Life Index (GIQLI)</measure>
    <time_frame>Up to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to functional recovery (days) after surgery</measure>
    <time_frame>Day 90</time_frame>
    <description>Functional recovery defined as all of the following:&#xD;
independently mobile at the preoperative level&#xD;
sufficient pain control with oral medication alone&#xD;
ability to maintain at least 50% daily required caloric intake&#xD;
no intravenous fluid administration&#xD;
no clinical signs of infection when other criteria were met</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Surgical Technique</condition>
  <arm_group>
    <arm_group_label>Side to side gastrojejunal reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The post-operative care: usual practise Follow-up: 90 days postoperatively&#xD;
At Day 90:&#xD;
a blood test for albumin and prealbumin&#xD;
a GIQLI questionnaire (quality of life score) to be completed by the patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terminolateral gastrojejunal reconstruction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The post-operative care: usual practise Follow-up: 90 days postoperatively&#xD;
At Day 90:&#xD;
a blood test for albumin and prealbumin&#xD;
a GIQLI questionnaire (quality of life score) to be completed by the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Reconstruction</intervention_name>
    <description>Lateral gastrojejunal Terminolateral gastrojejunal</description>
    <arm_group_label>Side to side gastrojejunal reconstruction</arm_group_label>
    <arm_group_label>Terminolateral gastrojejunal reconstruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient over 18 years old&#xD;
&#xD;
          -  to benefit from a cephalic duodenopancreatectomy whatever the indication (benign and&#xD;
             malignant tumor)&#xD;
&#xD;
          -  affiliated with a health insurance system&#xD;
&#xD;
          -  having received oral and written information about the protocol and having signed a&#xD;
             free and informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  associated organ resection except for portal vein or hepatic artery resection.&#xD;
&#xD;
          -  history of gastric or esophageal resection&#xD;
&#xD;
          -  person subject to legal protection (safeguard justice, trusteeship and guardianship)&#xD;
             and persons deprived of liberty&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  patient participating in another clinical trial that may interfere with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabien ROBIN, MD</last_name>
    <phone>02 99 28 69 89</phone>
    <email>fabien.robin@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent SULPICE, MD, PhD</last_name>
    <email>laurent.sulpice@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan GARNIER, MD</last_name>
      <email>garnierj@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier TURRINI, MD</last_name>
      <email>turrinio@ipc.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien ROBIN, MD</last_name>
      <phone>02 99 28 69 89</phone>
      <email>fabien.robin@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurent SULPICE, MD, PhD</last_name>
      <email>laurent.sulpice@chu-rennes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

